AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04339296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spencer
Description: The MDS dispenses medications on time with visual and audio reminders. The audio alert get louder if the plastic medication packet is not dispensed from the system. The MDS allows participants to dispense their medications early if they are going to be away from home. The system also displays personalized and health-condition speciﬁc questions. The pre-packaged medications are delivered by pharmacy that inserted directly into the spencer device. Spencer system is non-inclusive and approved by Health Canada.
Study NCT00003389 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Study NCT00784316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol, amiodarone
Description: to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
Study NCT00863434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV
Study NCT00863434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00863434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT05262946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sensorimotor training based on Feldenkrais method
Description: 8 weeks of balance and sensorimotor training twice a week
Study NCT05262946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: foot care education
Description: Recommendations for preventing foot ulcers
Study NCT05262946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: foot care education
Description: Recommendations for preventing foot ulcers
Study NCT05262946 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: drugs and diet usual care
Study NCT05262946 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: usual care
Description: drugs and diet usual care
Study NCT00002624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00002624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diagnostic thoracoscopy
Study NCT00002624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic thoracoscopy
Study NCT00002624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video-assisted surgery
Study NCT00002624 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00888992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline Service + 10 automated monitoring calls
Description: This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 10 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be two calls per a week for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
Study NCT00888992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline service + 20 automated monitoring calls
Description: This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 20 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be one automated call a day for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
Study NCT01797042 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Compliance
Description: Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks
Study NCT04568382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CI-PVP (context-informed pre-visit planning)
Description: may experience a single additional phone call from clinic staff in addition to the standard clinic staff chart review, email and/or phone call prior to diabetes office visit
Study NCT04568382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard PVP (pre-visit planning)
Description: standard clinic staff chart review, email and/or phone call prior to diabetes office visit
Study NCT01547494 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vegan Diet
Description: Vegan diet, which is devoid of animal products and minimal in fat
Study NCT01547494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mixture of omega3 and vitamins
Description: mixture of omega3 and vitamins
Study NCT01509066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Dietary approaches for PCOS
Study NCT01509066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Dietary approaches for PCOS
Study NCT01174602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy for AN (AN-EX/RP)
Description: 12 Sessions, 3 times per week. 90 minute sessions. Group therapy twice per week.
Study NCT01174602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation Therapy
Description: 12 Sessions, 3 times per week. 45 minute sessions. Group therapy twice per week.
Study NCT01294761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir, Darunavir/r
Description: An arm to change the regimen to: raltegravir and darunavir/ritonavir~Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID~from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD
Study NCT03799133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Florence device
Description: The Florence catheter will be placed at the beginning of the surgery and up to 72 hours in ICU.
Study NCT01908335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN-SA /RBV low dose
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Study NCT01908335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN-SA /RBV middle dose
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Study NCT01499979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In situ hypothermic perfusion
Description: In situ perfusion of the future remnant liver with chilled lactated Ringer's solution during liver resection.
Study NCT03111706 — intervention group
Intervention type: PROCEDURE
Intervention: Cesarean section
Description: During Cesarean delivery the lower uterine segment (LUS) was defined as the part of the uterus below the uterovesical peritoneal reflection. After opening the visceral peritoneum and performing the bladder dissection, the LUS was assessed for integrity of the CS scar by the operating surgeon to avoid bias by the sonographic findings. Scar dehiscence was defined as the presence of either transparent LUS with visible contents, presence of well-circumscribed scar defect or presence of frank uterine rupture.
Study NCT01014559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Naloxone
Description: Oxycodone Naloxone PR Tablet taken twice daily
Study NCT04124289 — intervention group
Intervention type: OTHER
Intervention: Pain measurement using 3 scales
Description: Patients will assess their pain after surgery using three different pain scales.
Study NCT02089659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally
Study NCT00194779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00194779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO
Study NCT00194779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00194779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00194779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study NCT00194779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT00194779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV
Study NCT00194779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: needle biopsy
Description: Correlative studies
Study NCT00194779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo definitive breast surgery
Study NCT00194779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT00194779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00194779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given PO
Study NCT00194779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO
Study NCT00194779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02128321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral
Study NCT02128321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: oral
Study NCT01014559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone PR Tablets
Description: Oxycodone PR Tablets taken twice daily
Study NCT03977805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: a single oral taking
Study NCT02813174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassionate Mind Training from Compassion-Focused Therapy
Study NCT04378036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Therapy
Description: The Neurodevelopmental Therapy rehabilitation program was determined according to the children's level of gross motor function, age, gender, mental state, and preferences. Neurodevelopmental Therapy program consists of the rehabilitation of muscle tone disorders, increasing sensory-perception-motor integrity, exercises to increase limb functions and body control, stretching and strengthening exercises for muscle shortness and weakness, exercises that include movements in daily life and training activities such as standing, walking, body care.
Study NCT04378036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hippotherapy Simulator
Description: Horse Riding Simulator (HRS) device was used as a hippotherapy simulator device. HRS is a device that moves forward, backward, backward-to-back, right-to-left swing and up-and-down swing in 3 dimensions, similar to the movements of a real horse, forming an 8-shaped movement on five axes. After the children sat in the saddle section, they were first taken to the warm-up speed program for 5 minutes, then to another one of the other speed levels (gradually moved to other speed levels as appropriate for the development and tolerance of children) and finally to the warm-up speed program for 5 minutes.
Study NCT04129710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 250 mg/m2 over 3 hours on day3
Study NCT04129710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGylated recombinant human granulocyte colony
Description: PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
Study NCT04129710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEGylated recombinant human granulocyte colony
Description: PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
Study NCT02970526 — intervention group
Intervention type: DRUG
Intervention: Oxaliplatin
Description: Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).
Study NCT01271257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
Study NCT02191540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abnoba Viscum F 20mg
Description: intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space
Study NCT01271257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
Study NCT02882386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Study NCT02882386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strength Training
Study NCT01908335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN-SA /RBV high dose
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Study NCT01908335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys /RBV
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Study NCT00613015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Study NCT00613015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Study NCT00613015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03167866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational SMS
Description: the participant receives a weekly text message that is aimed to increase motivation
Study NCT03167866 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: informational SMS
Description: the participant a weekly text message that is provides information on improving lifestyle
Study NCT04492306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dimethyl Sulfoxide
Description: DMSO \[(CH3)2SO\] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
Study NCT04492306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3M ESPE Single bond 2
Description: Total etch adhesive bond
Study NCT04492306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3M ESPE Single bond 2
Description: Total etch adhesive bond
Study NCT04492306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)
Description: Composite Resin
Study NCT04492306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)
Description: Composite Resin
Study NCT04492306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3m ESPE etch
Description: 32% phosphoric acid
Study NCT04492306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3m ESPE etch
Description: 32% phosphoric acid
Study NCT01058395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
Study NCT02840903 — intervention group
Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: 8 settings for CT Angiography as described in group description.
Study NCT02882386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk 1%
Study NCT02882386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate 80 (WPC-80)
Study NCT02882386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microparticulated whey
Study NCT02882386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey
Study NCT02882386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Native whey
Study NCT03976284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Garden-fresh produce and exercise
Description: The Garden-fresh produce and exercise (GFPE) health promotion intervention features 10 weekly sessions that take place after Sunday services in the Lincoln Memorial Church kitchen/meeting space. Each session includes a cooking demonstration focused on how to prepare and cook a meal composed of fiber-rich plant foods minimally processed. Each session also includes brief, didactic nutrition instruction and a 10-minute bout of physical activity.
Study NCT04474041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeQue Insight
Description: The Insight will be used to measure visual acuity and compared with a standard ETDRS eye chart.
Study NCT00117689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy
Study NCT00117689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: For a minimum of 3 months
Study NCT00117689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Between Day 3 the last dose of Thymoglobulin
Study NCT00117689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Between Day 3 the last dose of Thymoglobulin
Study NCT00117689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: for at least 1 month posttransplant
Study NCT00117689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: for at least 1 month posttransplant
Study NCT02282904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).~Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum).
Study NCT02282904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor peripheral blood stem cells.
Description: Infuse donor graft.
Study NCT02282904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide post transplant
Description: 50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
Study NCT02282904 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body 200cGy
Description: Day -1
Study NCT02128321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: oral
Study NCT01155973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EDUCORE intervention
Description: Direct exhibition of their cardiovascular risk with SCORE, visual images and documentation to the patients
Study NCT01155973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: SCORE oral information and counseling as standard practice care
Study NCT02394912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vena cava filter implantation (LUMIFI with Crux VCF System)
Study NCT02282904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg IV over one hour Day -6 and -5
Study NCT02282904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 over 30 minutes Day -6 through Day -2
Study NCT03133572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supraglottic airway
Description: Instead of using a conventional face mask to provide positive pressure ventilation during neonatal resuscitation we are using a supraglottic airway and a conventional bag.
Study NCT02282904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
Study NCT01504347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent recombinant OspA Lyme Borreliosis Vaccine
Description: Primary vaccination (6 study arms of 50 subjects each): 3 intramuscular injections containing either dose A, B or C in an adjuvanted or non-adjuvanted formulation (6 different formulations) given in monthly intervals (recruited in 3 sequential cohorts)
Study NCT01504347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent recombinant OspA Lyme Borreliosis Vaccine
Description: Booster vaccination 9-12 months after first vaccination in Section 1 subjects